(Reuters) – The U.S. Federal Trade Commission has allowed drugmaker Amgen Inc to move ahead with its $27.8 billion deal to buy Horizon Therapeutics, CNBC reported on Friday.
The FTC filed a lawsuit on May 16 aimed at stopping the transaction, but suspended its challenge in late August. The suspension enabled the FTC to consider whether the agency should settle the case.
The Thousand Oaks, California-based company announced plans to buy Horizon in December last year.
The FTC, Amgen and Horizon did not immediately respond to Reuters requests for comment.
Horizon’s shares rose 2.8% in premarket trading.
(Reporting by Manas Mishra in Bengaluru; Editing by Devika Syamnath)
Brought to you by www.srnnews.com
